Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
The Journal of Antimicrobial Chemotherapy|August 8, 2006
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatmentStefano Aquaro, Roberta D'Arrigo, Valentina Svicher, et al.
Antiviral Therapy|February 6, 2004
The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapyBruno Christian Ciancio, Maria Paola Trotta, Patrizia Lorenzini, et al.
The Journal of Infectious Diseases|April 19, 2008
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failureValentina Svicher, Stefano Aquaro, Roberta D'Arrigo, et al.
AIDS Research and Human Retroviruses|February 3, 2009
Dynamics of NRTI resistance mutations during therapy interruptionMaria Trignetti, Tobias Sing, Valentina Svicher, et al.
AIDS Research and Human Retroviruses|May 30, 2008
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAARTValerio Tozzi, Rita Bellagamba, Filippo Castiglione, et al.
Journal of Medical Virology|March 24, 2006
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovirMaria Paola Trotta, Sandro Bonfigli, Francesca Ceccherini-Silberstein, et al.
Antiviral Therapy|April 26, 2003
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutationMauro Zaccarelli, Carlo Federico Perno, Federica Forbici, et al.
Antiviral Research|February 26, 2011
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitroValentina Svicher, Emanuela Balestra, Valeria Cento, et al.
The Journal of Infectious Diseases|January 13, 2012
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencingDaniele Armenia, Ina Vandenbroucke, Lavinia Fabeni, et al.
Pageof 4